Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$3.85B |
| 2 |
Tesla
TSLA
|
+$1.78B |
| 3 |
Apple
AAPL
|
+$1.57B |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$1.49B |
| 5 |
Mastercard
MA
|
+$1.09B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Honeywell
HON
|
+$1.3B |
| 2 |
Phillips 66
PSX
|
+$650M |
| 3 |
iShares China Large-Cap ETF
FXI
|
+$475M |
| 4 |
State Street Materials Select Sector SPDR ETF
XLB
|
+$432M |
| 5 |
NRG Energy
NRG
|
+$387M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.59% |
| 2 | Financials | 9.21% |
| 3 | Consumer Discretionary | 7.33% |
| 4 | Healthcare | 5.59% |
| 5 | Communication Services | 5.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MAZE
4051
Maze Therapeutics
MAZE
$1.53B
| $161K | ﹤0.01% |
+14,644
| New | +$176K |
|
4052
Nektar Therapeutics
NKTR
$2.57B
| $161K | ﹤0.01% |
15,785
-5,936
| -27% | -$77.6K |
|
|
ARIS
4053
Aris Mining
ARIS
$3.66B
| $160K | ﹤0.01% |
34,576
-213
| -0.6% | -$846 |
|
4054
Shinhan Financial Group
SHG
$34.6B
| $160K | ﹤0.01% |
+5,000
| New | +$168K |
|
|
FFNW
4055
DELISTED
First Financial Northwest, Inc
FFNW
| $160K | ﹤0.01% |
7,052
-3,486
| -33% | -$74.6K |
|
4056
CPI Card Group
PMTS
$341M
| $160K | ﹤0.01% |
5,476
-2,236
| -29% | -$66.5K |
|
4057
PUT
Teladoc Health
TDOC
$1.22B
| $159K | ﹤0.01% |
+20,000
| New | +$202K |
|
|
SEPM
4058
FT Vest U.S. Equity Max Buffer ETF - September
SEPM
$31.5M
| $159K | ﹤0.01% |
5,343
+83
| +2% | +$2.49K |
|
4059
State Street SPDR S&P China ETF
GXC
$474M
| $159K | ﹤0.01% |
1,844
| – | – |
|
4060
Innovator US Equity Buffer ETF August
BAUG
$204M
| $159K | ﹤0.01% |
3,734
+396
| +12% | +$17.3K |
|
|
XYF
4061
X Financial
XYF
$202M
| $158K | ﹤0.01% |
+11,000
| New | +$109K |
|
4062
MediWound
MDWD
$179M
| $157K | ﹤0.01% |
10,127
-2,285
| -18% | -$40.9K |
|
4063
Kyverna Therapeutics
KYTX
$498M
| $157K | ﹤0.01% |
81,390
-8,196
| -9% | -$24.2K |
|
4064
Innovator US Equity Ultra Buffer ETF April
UAPR
$159M
| $157K | ﹤0.01% |
5,256
+5,162
| +5,491% | +$160K |
|
4065
InfuSystem Holdings
INFU
$244M
| $156K | ﹤0.01% |
28,977
-2,502
| -8% | -$18.3K |
|
4066
GSK
GSK
$101B
| $155K | ﹤0.01% |
4,009
-45,619
| -92% | -$1.67M |
|
|
EWCZ
4067
DELISTED
European Wax Center
EWCZ
| $155K | ﹤0.01% |
39,251
-18,813
| -32% | -$112K |
|
4068
INmune Bio
INMB
$56.6M
| $155K | ﹤0.01% |
19,842
-12,177
| -38% | -$96.7K |
|
4069
Escalade
ESCA
$284M
| $155K | ﹤0.01% |
10,116
-4,925
| -33% | -$74.2K |
|
4070
Smith-Midland
SMID
$147M
| $154K | ﹤0.01% |
4,972
-2,268
| -31% | -$83.6K |
|
4071
AMES National
ATLO
$281M
| $154K | ﹤0.01% |
8,810
-4,405
| -33% | -$78.8K |
|
4072
State Street SPDR S&P Aerospace & Defense ETF
XAR
$6.64B
| $154K | ﹤0.01% |
960
| – | – |
|
4073
iShares MSCI EAFE Value ETF
EFV
$30.1B
| $154K | ﹤0.01% |
2,615
| – | – |
|
4074
Alector
ALEC
$240M
| $154K | ﹤0.01% |
125,086
-51,483
| -29% | -$83.8K |
|
4075
Universal Electronics
UEIC
$75.8M
| $154K | ﹤0.01% |
25,133
+2,407
| +11% | +$21.1K |
|
Similar funds
Barclays's Q1 2025 Portfolio in Review
As of Q1 2025, Barclays held 5,710 positions worth $353B, down 1.2% from $357B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Barclays deployed $16.5B of net new capital in Q1 2025, opening 439 new positions and adding to 1,449 existing holdings. Its largest new stake was JPMorgan BetaBuilders USD High Yield Corporate Bond ETF: 318,453 shares worth $14.7M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 18% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Honeywell, an estimated $1.3B trimmed.
- Barclays's largest Q1 2025 buy was JPMorgan BetaBuilders USD High Yield Corporate Bond ETF: 318,453 shares worth $14.7M.
- Barclays added most to State Street SPDR S&P 500 ETF Trust in Q1 2025, an estimated $3.85B increase.
- Barclays's biggest Q1 2025 reduction was Honeywell, cutting an estimated $1.3B.
- Barclays fully exited Smartsheet Inc. in Q1 2025, selling an estimated $45.7M.
- Barclays's ten largest holdings make up 37% of its $353B portfolio in Q1 2025.
- Barclays opened 439 new positions and closed 470 in Q1 2025.
- Barclays's portfolio value fell 1.2% quarter-over-quarter to $353B.
Based on Barclays's 13F filing for Q1 2025, filed 15 May 2025.